ClinicalTrials.gg
RecruitingNCT06178510POSITiVE IIUpdated Oct 30, 2026

I-ASV in Cardiac Surgery

An interventional study of INTELLiVENT-ASV. in Ventilator Lung, sponsored by Medical University of Vienna. Recruiting at 1 site in Austria. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Medical University of Vienna · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.
Updated Oct 30, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
328
Allocation
Randomized
Ages
18 Years to 120 Years
Sex
All
01

Study summary

'POStoperative INTELLiVENT-adaptive support VEntilation in cardiac surgery patients II (POSITiVE II) is an investigator-initiated, international, multicenter, parallel, randomized clinical trial in patients after cardiac surgery.

Read the detailed description

To compare INTELLiVENT-ASV with conventional ventilation with respect to (i.) quality of ventilation; and (ii.) ICU nursing staff workload in an international cohort of participants receiving postoperative ventilation after cardiac surgery. This study will also determine the effects of INTELLiVENT-ASV on clinical outcomes, including (iii.) duration of postoperative ventilation and (iv.) length of stay in ICU.

02

Conditions studied

  • Ventilator Lung

Keywords

  • Adaptative Support Ventilation
  • INTELLiVENT
  • Cardiac Surgery
  • Workload
03

In context

Lead sponsor

Medical University of Vienna is the lead sponsor of 1,111 studies on the registry; 186 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. aged > 18 years of age;
  • 2. scheduled for elective cardiac surgery; and
  • 3. expected to receive postoperative ventilation in the ICU for > 2 hours.

Exclusion criteria

Exclusion Criteria:

  1. any emergency or semi-elective surgery (precluding informed written consent);
  2. any surgery other than CABG, valve replacement or repair, or a combination (i.e., patients planned for surgery for congenital heart disease, or scheduled for heart transplantation are excluded);
  3. enrolled in another interventional trail;
  4. no written obtained;
  5. history of recent pneumectomy or lobectomy;
  6. history of with oxygen at home;
  7. > 35;
  8. preoperative (FeV1)/forced vital capacity (VC) \< 50% (if available);
  9. preoperative arterial oxygen partial pressure (PaO2) \< 60 mm Hg (at room air);
  10. preoperative arterial carbon dioxide partial pressure (PaCO2) > 50 mm Hg;
  11. preoperative \< 30% (if available);
  12. preoperative systolic pulmonary artery pressure > 60 mm Hg (if available);
  13. preoperative left ventricular mechanical support, e.g., Impella®; or
  14. preoperative use of veno-venous or veno-arterial extracorporeal support

    At the end of surgery, patients are additionally excluded if a patient:

  15. cannot be weaned from the extracorporeal support; or
  16. unexpectedly needs implementation of an assist device
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
328 participants (estimated)

Study arms

  • Other
    INTELLiVENT-ASV

    The ventilator set parameters such as tidal volume, respiratory rate, and positive end-expiratory pressure to ensure adequate ventilation and oxygenation. The investigators monitor it and define clinical target.

    Device: INTELLiVENT-ASV.

  • No intervention
    conventional ventilation

    The investigators set and monitor parameters such as tidal volume, respiratory rate, and positive end-expiratory pressure to ensure adequate ventilation and oxygenation.

Interventions

  • DeviceINTELLiVENT-ASV.

    INTELLiVENT-ASV® is a closed-loop ventilation mode that automatically adjusts respiratory rate and tidal volume according to the oxygen and ventilatory patient needs

06

What researchers measure

Primary outcomes

  1. Quality of ventilation

    The primary outcome is quality of ventilation, which is the proportion of time spent in three predefined and previously used zones of ventilation in the first 2 hours of postoperative ventilation. * An optimal zone = Tidal volume (TV) = 4-8 ml/kg of the predicted body weight (PBW) with an EtCO2 = 30-45mmHg, a plateau pressure = \<31cmH2O and SpO2 = 93-98%. * An acceptable zone = TV = 8-12 ml/kg of PBW with an EtCO2 = 25-30 or 45-50mmHg, a plateau pressure = 31-35 cmH2O and SpO2 = 85-93% or \>98%. * An unacceptable zone = TV \>12 ml/kg of PBW or an EtCO2 = \<25 or \>50mmHg, plateau pressure \>35 cmH2O or SpO2 = \<85%.

    Time frame: During the first 2 hours, since admission on the ICU with the start of the intervention ventilation mode.

Secondary outcomes

  1. ICU nursing staff workload

    ICU nursing staff workload, which is captured by the ventilator software collecting data on alarms (number of alarms, types of alarm, duration of alarm, responses to alarm, alarm settings and adjustments, breath-by-breath alarm data, and any manual intervention at the ventilator) during postoperative care in the ICU

    Time frame: 24 hours

  2. Duration of postoperative ventilation

    The time from admission on the ICU until extubation.

    Time frame: 8 hours or until extubation

  3. Patient-ventilator asynchrony

    patient-ventilator asynchrony requiring deepening of sedation and/or administration of muscle relaxants

    Time frame: Up to 6 hours of mechanical ventilation time

  4. Proportion of breath spent in zones of ventilation

    Proportion of breaths spent in predefined and previously used zones of ventilation in the first 6 hours of postoperative ventilation. * An optimal zone = Tidal volume (TV) = 4-8 ml/kg of the predicted body weight (PBW) with an EtCO2 = 30-45mmHg, a plateau pressure = \<31cmH2O and SpO2 = 93-98%. * An acceptable zone = TV = 8-12 ml/kg of PBW with an EtCO2 = 25-30 or 45-50mmHg, a plateau pressure = 31-35 cmH2O and SpO2 = 85-93% or \>98%. * An unacceptable zone = TV \>12 ml/kg of PBW or an EtCO2 = \<25 or \>50mmHg, plateau pressure \>35 cmH2O or SpO2 = \<85%.

    Time frame: Up to 6 hours of mechanical ventilation time

  5. ICU length of stay

    Length of stay in the ICU

    Time frame: From date of ICU admission until the date of ICU discharge, assessed up to 30 days

  6. Hospital length of stay

    Length of stay in hospital

    Time frame: From date of hospital admission until the date of hospital discharge, assessed up to 30 days

  7. Mortality

    Mortality in ICU or hospital

    Time frame: 28-day

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bernardi MH, Bettex D, Buiteman-Kruizinga LA, de Bie A, Hoffmann M, de Kleijn J, Serafini SC, Molenaar MA, Paulus F, Persec J, Neto AS, Schuepbach R, Severgnini P, Sribar A, Schultz MJ, Tschernko E; POSITiVE II-investigators. POStoperative INTELLiVENT-adaptive support VEntilation in cardiac surgery patients (POSITiVE) II-study protocol of a randomized clinical trial. Trials. 2024 Jul 3;25(1):449. doi: 10.1186/s13063-024-08296-2. PubMed 38961468 ↗

Individual participant data

Plan to share: Undecided — The results of the study will find their way into (inter-) national scientific journals and guidelines. We will submit a summary of results to scientific journals in the field of anesthesiology.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2024 (actual). Primary completion is estimated for Apr 2027, 35 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Jun 2025 → Apr 2027 and completion Dec 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2023
First posted
Dec 21, 2023
StartActual
May 31, 2024
Primary completionEst.
Apr 2027was Jun 2025
CompletionEst.
Dec 31, 2027was Dec 2025
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Medical University of Vienna · Vienna, Austria
Show 1 removed
  • Medical University of Vienna · Vienna, Austria
Oct 30, 2026
Primary completion
Jun 2025→Apr 2027
Oct 30, 2026
Study completion
Dec 2025→Dec 31, 2027
Oct 30, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 38961468 ↗
Oct 30, 2026
Sponsor
Collaborators added: Università degli Studi dell'Insubria; collaborators removed: Università degli Studi dell'Insubria
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 38961468 ↗
    1 site added, 1 site removed
    Show site
    • Medical University of Vienna · Vienna, Austria
    Show 1 removed
    • Medical University of Vienna · Vienna, Austria
    Primary completion Jun 2025→Apr 2027
    Study completion Dec 2025→Dec 31, 2027
    Sponsor Collaborators added: Università degli Studi dell'Insubria; collaborators removed: Università degli Studi dell'Insubria
    + 4 other changes: identifiers, verification date, oversight details and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06178510
Collaborators
University Hospital Dubrava, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), University of Zurich, Università degli Studi dell'Insubria
Responsible party
Prof. Dr. Edda Tschernko (Principal Investigator, Medical University of Vienna) — Principal investigator
First posted
Dec 21, 2023
Start date
May 31, 2024
Primary completion
Apr 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Edda Tschernko, MD
Contact
edda.tschernko@meduniwien.ac.at
00 43 1 40400 41090
Martin H. Bernardi, MD
Contact
martin.bernardi@meduniwien.ac.at
00 43 1 40400 41090
Edda Tschernko, MD
principal investigator · Medical University of Vienna

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion